BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 16724649)

  • 1. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
    Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N
    J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer.
    Nyárády Z; Németh A; Bán A; Mukics A; Nyárády J; Ember I; Olasz L
    Anticancer Res; 2006; 26(2B):1557-62. PubMed ID: 16619571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilocarpine in the prevention of postirradiation xerostomia.
    Lajtman Z; Krajina Z; Krpan D; Vincelj J; Borcić V; Popović-Kovacić J
    Acta Med Croatica; 2000; 54(2):65-7. PubMed ID: 11028111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.
    Sangthawan D; Watthanaarpornchai S; Phungrassami T
    J Med Assoc Thai; 2001 Feb; 84(2):195-203. PubMed ID: 11336078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia.
    Jha N; Seikaly H; Harris J; Williams D; Sultanem K; Hier M; Ghosh S; Black M; Butler J; Sutherland D; Kerr P; Barnaby P
    Head Neck; 2009 Feb; 31(2):234-43. PubMed ID: 19107948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
    Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
    Fisher J; Scott C; Scarantino CW; Leveque FG; White RL; Rotman M; Hodson DI; Meredith RF; Foote R; Bachman DG; Lee N
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):832-6. PubMed ID: 12788192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia.
    Ringash J; Warde P; Lockwood G; O'Sullivan B; Waldron J; Cummings B
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1403-7. PubMed ID: 15817343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer.
    Johnson JT; Ferretti GA; Nethery WJ; Valdez IH; Fox PC; Ng D; Muscoplat CC; Gallagher SC
    N Engl J Med; 1993 Aug; 329(6):390-5. PubMed ID: 8326972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.
    Scrimger R; Kanji A; Parliament M; Warkentin H; Field C; Jha N; Hanson J
    Am J Clin Oncol; 2007 Jun; 30(3):271-7. PubMed ID: 17551304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing radiation induced xerostomia.
    Koukourakis MI; Danielidis V
    Cancer Treat Rev; 2005 Nov; 31(7):546-54. PubMed ID: 16257125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation-induced xerostomia: how dry is your patient?
    Bruce SD
    Clin J Oncol Nurs; 2004 Feb; 8(1):61-7. PubMed ID: 14983765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
    Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
    Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing complications of radiation therapy in head and neck cancer patients: Part I. Management of xerostomia.
    Ngeow WC; Chai WL; Rahman RA; Ramli R
    Singapore Dent J; 2006 Dec; 28(1):1-3. PubMed ID: 17378333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of pilocarpine and biperiden on pH value and calcium, phosphate, and bicarbonate concentrations in saliva during and after radiotherapy for head and neck cancer.
    Rode M; smid L; Budihna M; Gassperssic D; Rode M; Soba E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Nov; 92(5):509-14. PubMed ID: 11709686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of saliva in oral health: strategies for prevention and management of xerostomia.
    Brosky ME
    J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.